We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current IOVA market cap is 694.58M. The company's latest EPS is USD -1.1145 and P/E is -1.86.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 715k | 31.11M | 58.56M | 73.69M | 49.32M |
| Operating Income | -117.72M | -101.91M | -89.07M | -86.58M | -121.22M |
| Net Income | -112.98M | -97.1M | -83.54M | -78.56M | -116.16M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 1.19M | 164.07M |
| Operating Income | -261.94M | -342.7M | -398.88M | -460.56M | -395.28M |
| Net Income | -259.58M | -342.25M | -395.89M | -444.04M | -372.18M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 869.83M | 964.32M | 991.12M | 910.43M | 966.74M |
| Total Liabilities | 189.81M | 195.78M | 217.66M | 200.02M | 198.88M |
| Total Equity | 680.02M | 768.54M | 773.46M | 710.41M | 767.87M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 768.46M | 777.33M | 663.98M | 780.35M | 910.43M |
| Total Liabilities | 111.96M | 155.67M | 164.34M | 195.74M | 200.02M |
| Total Equity | 656.5M | 621.66M | 499.64M | 584.61M | 710.41M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -122.28M | -220.71M | -279.68M | -352.98M | -103.69M |
| Investing | -111.51M | -71.29M | -120.09M | -96.41M | 15.87M |
| Financing | 193.58M | 346.4M | 388.36M | 390.66M | 143.32M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -205.13M | -227.94M | -292.76M | -361.82M | -352.98M |
| Investing | -317.85M | 132k | 256.46M | -155.24M | -96.41M |
| Financing | 576.42M | 239.27M | 190.15M | 462.96M | 390.66M |
| Market Cap | 694.58M |
| Price to Earnings Ratio | -1.86 |
| Price to Sales Ratio | 4.21 |
| Price to Cash Ratio | 5.97 |
| Price to Book Ratio | 0.97 |
| Dividend Yield | - |
| Shares Outstanding | 333.93M |
| Average Volume (1 week) | 14.63M |
| Average Volume (1 Month) | 12.14M |
| 52 Week Change | -74.16% |
| 52 Week High | 12.505 |
| 52 Week Low | 1.6385 |
| Spread (Intraday) | 0.01 (0.48%) |
| Company Name | Iovance Biotherapeutics Inc |
| Address |
2140 s dupont hwy camden, delaware 19934 |
| Website | https://www.iovance.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
